Clinical Trial

A Study of GC203 TIL in Advanced Malignant Solid Tumors

Study acronym: KUNLUN-001
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-04-16; most recent amendment 2025-12-04.
Status change: Not Yet Recruiting → Recruiting 2024-06-19
Trial Details
NCT Number NCT06375187
Lead Sponsor Shanghai Juncell Therapeutics
Conditions Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer, Lung Cancer
Enrollment 18 participants
Start Date 2024-05-29
Primary Completion 2026-11-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-11